ArticleFrontiers in oncology2025
Metabolic reprogramming-driven stratification and therapeutic targeting in lung adenocarcinoma: implications for prognosis and personalized treatment.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatially resolved lactate-glycolysis transcriptional programs are associated with neutrophil-enriched immune remodeling in lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Article
- Lipid metabolism-related gene expression predicts prognostic outcomes in lung adenocarcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic reprogramming is a hallmark of lung adenocarcinoma (LUAD) progression and therapy resistance, yet its clinical integration for prognosis and treatment remains limited. This study aimed to develop a metabolism-related prognostic score (MRPs) and investigate its biological, immunological, and therapeutic implications in LUAD. Methods: Transcriptomic and clinical data from TCGA and GEO were used to construct a prognostic model based on metabolism-associated genes Results: The MRPs model stratified LUAD patients into two subgroups with distinct prognoses. The high-risk MRP I subgroup showed enhanced oxidative phosphorylation, cell cycle activity, and protein synthesis, along with suppressed immune infiltration and lower immune scores. WARS2 was highly expressed in malignant epithelial cells and associated with proliferative and metabolic programs at both bulk and single-cell levels. WARS2-positive cells exhibited increased intercellular communication Conclusion: This study presents a novel MRPs system that captures LUAD metabolic and immune heterogeneity and surpasses traditional clinicopathologic parameters in prognostic performance. WARS2 emerges as a functional driver and therapeutic target. These findings offer a comprehensive framework for metabolic-state-based stratification and personalized treatment strategies in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.